Treatment-related skin reactions in enfortumab vedotin as a surrogate marker of survival and treatment response DOI Creative Commons
Jun Nagayama, Satoshi Inoue,

Hiroki Sai

et al.

International Journal of Clinical Oncology, Journal Year: 2024, Volume and Issue: 30(2), P. 267 - 276

Published: Dec. 16, 2024

Language: Английский

Impact of Skin Adverse Events on Prognosis in Patients With Locally Advanced or Metastatic Urothelial Carcinoma Treated With Enfortumab Vedotin: A Real‐World Multicenter Study DOI Open Access

Kai Ozaki,

Hayato Yamamoto,

Yuya Sekine

et al.

International Journal of Urology, Journal Year: 2025, Volume and Issue: unknown

Published: March 3, 2025

ABSTRACT Objective We aimed to investigate the impact of skin adverse events (AEs) enfortumab vedotin (EV) on prognosis in patients with locally advanced or metastatic urothelial carcinoma real‐world practice. Methods This study analyzed data from 115 carcinoma. evaluated association between EV dose and AEs these patients. The progression‐free survival (PFS) overall (OS) was assessed using Kaplan–Meier curves Cox regression analysis. Results median PFS OS were 8.1 14.5 months, respectively. reduction observed 68 (59.1%) An estimated amount first, second, seventh cycles 95%, 85%, 81%, 69 (60%) cases, they within 1 month 53 (76.8%) cases. Patients had significantly longer compared those without AEs. Multivariable analysis showed a significant prolonged OS. Conclusions Skin associated AEs, although required 59.1% Careful adjustment may be crucial for long‐term use optimizing oncological outcomes.

Language: Английский

Citations

2
Influence of best objective response to first‐line treatment on survival outcomes in advanced urothelial carcinoma in the era of sequential therapy with enfortumab vedotin DOI Creative Commons
Kohei Kobatake, Keisuke Goto, Yuki Sakamoto

et al.

International Journal of Urology, Journal Year: 2025, Volume and Issue: unknown

Published: Feb. 10, 2025

Objective This study evaluated whether first‐line treatment affects survival outcomes in patients with advanced urothelial carcinoma undergoing sequential therapy chemotherapy, immune checkpoint inhibitors, and enfortumab vedotin. Methods multicenter retrospective included 57 treated at Hiroshima University Hospital its affiliated institutions between 2009 2024. Patients received chemotherapy as a (gemcitabine plus cisplatin or carboplatin), followed by second‐line inhibitors (pembrolizumab avelumab) third‐line Assessed overall time to failure. Cox regression analysis identified prognostic factors for survival. Results Over median follow‐up of 20.5 months, was not reached after treatment. Gemcitabine selected 31.6% cases, while gemcitabine carboplatin chosen 68.4% cases the treatment; subsequently, 66.7% pembrolizumab, 33.3% avelumab who achieved complete partial response had significantly longer survivals from both vedotin initiation than those stable progressive disease. In that responses, more frequently therapy. However, treatment, multivariate only disease significant predictor worse Conclusion The best predicted following underscoring value carcinoma.

Language: Английский

Citations

1
Editorial Comment to “Impact of Skin Adverse Events on Prognosis in Patients With Locally Advanced or Metastatic Urothelial Carcinoma Treated With Enfortumab Vedotin: A Real‐World Multicenter Study” DOI

Nozomi Hayakawa,

Eiji Kikuchi

International Journal of Urology, Journal Year: 2025, Volume and Issue: unknown

Published: April 7, 2025

Language: Английский

Citations

0
Efficacy of Enfortumab Vedotin Ineligible criTeriA (EVITA) in advanced urothelial carcinoma DOI
Takafumi Fukushima, Kazuyuki Numakura,

M. Shiohara

et al.

Published: April 3, 2025

Abstract Enfortumab Vedotin Ineligible criTeriA (EVITA) were proposed for the selection of patients to receive enfortumab vedotin (EV) and pembrolizumab treatment. However, usefulness these criteria has not been verified. We investigated efficacy ofthe EVITA in with unresectable or metastatic urothelial carcinoma (UC) who treated EV monotherapy real-world practice. retrospectively analyzed data from 301 unresectableor UC underwent first-line chemotherapy.We evaluated numbers fulfilling EVITAand relationship safety monotherapy. Of patients, 4.3% (n = 13) fulfilled chemotherapy. The major factor contributing a higher score was renal dysfunction. 135 subsequent therapy, number had no influence on frequency all-grade grade ≥3 adverse events. Oncological outcomes associated EVITA. In conclusion, we observed 14.8% at time respectively. could be confirmed.

Language: Английский

Citations

0
Treatment-related skin reactions in enfortumab vedotin as a surrogate marker of survival and treatment response DOI Creative Commons
Jun Nagayama, Satoshi Inoue,

Hiroki Sai

et al.

International Journal of Clinical Oncology, Journal Year: 2024, Volume and Issue: 30(2), P. 267 - 276

Published: Dec. 16, 2024

Language: Английский

Citations

2